B · Normal
[Warner Pharmaceuticals: Subsidiary iguratimod API received marketing approval] On September 2, Warner Pharmaceuticals (688799.SH) announced that the company's wholly-owned subsidiary Chiral Drugs has received the "Notice of Approval of Marketing Application for Chemical APIs" for iguratimod issued by the State Food and Drug Administration. The API is mainly used to treat active rheumatoid arthritis. This approval will further enrich the company's product line and enhance its core competitiveness. However, the production and sales time is subject to uncertainty due to GMP inspections and market environment.
Comments